New research from Washington University provides the first
evidence of a human antibody capable of protecting fetuses from the Zika virus.
Not exact matches
Mouse study offers
evidence of antibody «enhancement,» which could explain severity
of human cases
Dr Hayday observes: «Such striking correlations with type 1 diabetes were not evident for any other naturally arising anti-interleukin or anti-interferon
antibodies, providing perhaps the strongest
evidence yet in
humans that interferon - alpha may contribute critically to the natural progression
of type 1 diabetes.»
They go on to say that «since no single broadly neutralizing
antibody combines the entire range
of mechanistic features anticipated to support in vivo efficacy, our study adds further
evidence that combinations
of such
antibodies need to be considered for
human application.»
In our study, 2
of 81, or 2.5 %
of random adult blood donors exhibited borderline titers
of neutralizing
antibody to TMAdV, indicating either a low prevalence
of TMAdV in the
human population or cross-reactivity to a related virus (although no
evidence of cross-reactivity was found with HAdV serotypes 1 through 35).